127 related articles for article (PubMed ID: 36709835)
1. Physicochemical characterization and functionality comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
Kinzer JL; Halseth TA; Kang J; Kim SY; Kumaran P; Ford M; Saveliev S; Skilton SJ; Schwendeman A
Int J Pharm; 2023 Mar; 635():122646. PubMed ID: 36709835
[TBL] [Abstract][Full Text] [Related]
2. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
Storz U
Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
[TBL] [Abstract][Full Text] [Related]
3. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.
Lim H; Lee SH; Lee HT; Lee JU; Son JY; Shin W; Heo YS
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518978
[TBL] [Abstract][Full Text] [Related]
4. Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect
Arens K; Filippis C; Kleinfelder H; Goetzee A; Reichmann G; Crauwels P; Waibler Z; Bagola K; van Zandbergen G
Front Immunol; 2018; 9():1772. PubMed ID: 30108591
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
6. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.
Lee C; Jeong M; Lee JJ; Seo S; Cho SC; Zhang W; Jaquez O
MAbs; 2017; 9(6):968-977. PubMed ID: 28640663
[TBL] [Abstract][Full Text] [Related]
9. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
Rawla P; Sunkara T; Raj JP
J Inflamm Res; 2018; 11():215-226. PubMed ID: 29844695
[TBL] [Abstract][Full Text] [Related]
10. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
11. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
Shealy DJ; Cai A; Staquet K; Baker A; Lacy ER; Johns L; Vafa O; Gunn G; Tam S; Sague S; Wang D; Brigham-Burke M; Dalmonte P; Emmell E; Pikounis B; Bugelski PJ; Zhou H; Scallon BJ; Giles-Komar J
MAbs; 2010; 2(4):428-39. PubMed ID: 20519961
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
13. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
[TBL] [Abstract][Full Text] [Related]
14. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
15. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
[TBL] [Abstract][Full Text] [Related]
16. Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
Hatfield G; Tepliakova L; Gingras G; Stalker A; Li X; Aubin Y; Tam RY
Front Immunol; 2022; 13():972168. PubMed ID: 36304448
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for the treatment of Crohn's disease.
Devlin SM; Panaccione R
Expert Opin Biol Ther; 2008 Jul; 8(7):1011-9. PubMed ID: 18549330
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
